Free Trial

Thermo Fisher (TMO; A3, A-, A-) {TMO US Equity} 1Q results

HEALTHCARE

In-line results, BS little changed. Cash lines are unch today. Sizeable +20bp pickup remains to one-notch lower Stryker (SYK; Baa1 Pos, BBB+ S) - reports next week. No firm view from us on either yet.


  • Slight beat on 1Q revenue at $10.35b (c$10.17b) at a organic growth of neg. 4% yoy. Adj. EBIT margin also beat at 22% (c21%) & is unch yoy.
  • FCF was $908m from the $1.3b in operating cash flows. $3b in buybacks over qtr. Note qtryl dividend was already bumped to 39c/share (~$600m/yr).* Marginal bump to FY guidance; revenue expected at $42.3-43.3b range & EPS $21.14-$22.02.
  • Gross leverage at 3.3x (Q4 3.2x) net at 2.6x (Q4 2.5x) with liquidity at $7.25b against $35.6b in debt.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.